Guangyan Du

• Led an early project as the medicinal chemistry lead, actively engaging cross-functional team members, driving hit identification, and shaping the program’s early strategy. • Managed chemistry CRO teams by leading the development of a new technology platform supporting multiple programs, while guiding problem-solving efforts and adjusting target priorities as needed.

• Worked on a degrader project in oncology and discovered a novel scaffold that demonstrated strong activity, selectivity, and favorable PK properties, leading to the nomination of a development candidate. • Key contributor to building the Targeted Protein Degradation (TPD) platform and introduced Direct to Biology (D2B) technology as a key component of the platform which benefit all TPD projects and improved the efficiency and productivity.

Worked on an immune disease inhibitor project from hit-to-lead through lead optimization, successfully identifying a selectivity handle via structure-based design to mitigate activity against the primary off-target. Delivered a development candidate BLU808 that has advanced to clinical trial.

• Designed IMiDs libraries that led to the discovery of numerous molecules targeting both G-loop and non-G-loop degrons. • Worked on multiple heterobifunctional degrader projects targeting various proteins, including HCV NS3/4A protease, Dengue capsid, FGFR2, CDK7, MALT1, CRBN, and VHL. • Explored the substrate scope of the novel E3 ligase KEAP1 to assess its potential for targeted protein degradation. • Leveraged a covalent strategy to enhance potency against SRC and improve target selectivity.